Immune thrombocytopenia

N Cooper, W Ghanima - New England Journal of Medicine, 2019 - Mass Medical Soc
Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

C Neunert, W Lim, M Crowther, A Cohen… - Blood, The Journal …, 2011 - ashpublications.org
Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …

Nanocarriers as an emerging platform for cancer therapy

D Peer, JM Karp, S Hong, OC Farokhzad… - Nano-enabled …, 2020 - taylorfrancis.com
The delivery of drugs through targeted nanocarriers that are internalized by cells provides
an alternative route to diffusion of drugs into cells. Growth factor or vitamin interactions with …

International consensus report on the investigation and management of primary immune thrombocytopenia

D Provan, R Stasi, AC Newland… - Blood, The Journal …, 2010 - ashpublications.org
Previously published guidelines for the diagnosis and management of primary immune
thrombocytopenia (ITP) require updating largely due to the introduction of new classes of …

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working …

F Rodeghiero, R Stasi, T Gernsheimer… - Blood, The Journal …, 2009 - ashpublications.org
Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely
dependent on clinical expertise and observations more than on evidence derived from …

Splenectomy for immune thrombocytopenia: down but not out

S Chaturvedi, DM Arnold… - Blood, The Journal of the …, 2018 - ashpublications.org
Splenectomy is an effective therapy for steroid-refractory or dependent immune
thrombocytopenia (ITP). With the advent of medical alternatives such as rituximab and …

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and …

KR Carson, AM Evens, EA Richey… - Blood, The Journal …, 2009 - ashpublications.org
Rituximab improves outcomes for persons with lymphoproliferative disorders and is
increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients …

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

VL Patel, M Mahévas, SY Lee, R Stasi… - Blood, The Journal …, 2012 - ashpublications.org
Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet
responses without continued dosing are limited. Whereas complete responses (CRs) to B …

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo …

JB Bussel, D Provan, T Shamsi, G Cheng, B Psaila… - The Lancet, 2009 - thelancet.com
Background Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that
stimulates thrombopoiesis, leading to increased platelet production. This study assessed the …

CD20 deficiency in humans results in impaired T cell–independent antibody responses

TW Kuijpers, RJ Bende, PA Baars… - The Journal of …, 2010 - Am Soc Clin Investig
CD20 was the first B cell differentiation antigen identified, and CD20-specific mAbs are
commonly used for the treatment of B cell malignancies and autoantibody-mediated …